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PURPOSE. We determined bioactivity of lysophospholipids generated by degradation of the
low-density (LDL), very low-density (VLDL), and high-density (HDL) lipoproteins with hepatic
lipase (HL), cholesterol esterase (CE), and lipoprotein-associated phospholipase A2 (Lp-PLA2).
METHODS. The LDL, VLDL, and HDL were treated with HL, CE, and Lp-PLA2 after
immobilization on plates, and complement activation studies were performed with diluted
human serum. Complement component 3 (C3) fixation, a marker for complement activation,
was determined with a monoclonal anti-human C3d antibody. Enzymatic properties of HL and
CE were assayed with triglyceride and phosphatidylcholine substrates for triglyceride
hydrolase and phospholipase A activities. The ARPE-19 cells were used for viability studies.
RESULTS. The HL degradation of human lipoproteins LDL, VLDL, or HDL results in the
formation of modified lipoproteins that can activate the complement pathway. Complement
activation is dose- and time-dependent upon HL and occurs via the classical pathway.
Enzymatic studies suggest that the phospholipase A1 activity of HL generates complementactivating lysophospholipids. C-reactive protein (CRP), known to simultaneously interact
with complement C1 and complement factor H (CFH), further enhances HL-induced
complement activation. The lysophospholipids, 1-Palmitoyl-sn-glycero-3-phosphocholine and
1-Oleoyl-sn-glycero-3-phosphocholine, can be directly cytotoxic to ARPE-19 cells.
CONCLUSIONS. The HL degradation of lipoproteins, known to accumulate in the outer retina and
in drusen, can lead to the formation of bioactive lysophospholipids that can trigger complement
activation and induce RPE cellular dysfunction. Given the known risk associations for agerelated macular degeneration (AMD) with HL, CRP, and CFH, this study elucidates a possible
damage pathway for age-related macular degeneration (AMD) in genetically predisposed
individuals, that HL activity may lead to accumulation of lysophospholipids to initiate
complement activation, with CFH dysregulation exacerbating the effects of this process.
Keywords: age-related macular degeneration, hepatic lipase, lipoproteins, lysophospholipids,
complement activation, C-reactive protein, RPE cytotoxicity

ge-related macular degeneration (AMD) is a degenerative
eye disease associated with genetic and environmental risk
factors. This disease is the leading cause of vision loss in senior
populations of developed countries and remains a major public
health problem.1 Drusen commonly develop in the aging
macula and, when present in large size or number, represent a
hallmark risk factor for late stage AMD. There are two advanced
forms of AMD, neovascular disease, in which new blood vessels
grow under or within the retinal layers, and atrophic disease, in
which there is damage to photoreceptors and RPE cells without
abnormal vascularization. The neovascular form of AMD
currently is treated with anti-VEGF therapy but may develop
associated anatomic complications, such as hemorrhage,
fibrosis, and RPE rips that limit visual outcomes. There is no
known treatment for the atrophic form of AMD, though
antioxidants and carotenoid supplements may slow progression
of the disease. Eyes may develop both forms of AMD over the
course of a lifetime.
Genetic studies have identified that the complement
pathway and another locus, in chromosomal region 10q26,

confer major susceptibilities to the disease.2–8 Several additional loci with smaller odds ratios also have been shown to be
associated with AMD, including apolipoprotein E (apoE) and
hepatic lipase.9–11 Smaller odds ratio and lower allele frequency
attributable to certain genetic variants do not necessarily reflect
the role of a gene and its encoded protein in the pathophysiology of disease. A single nucleotide polymorphism (SNP) can
alter gene expression and/or its protein function, but the level
of alteration can vary, making it difficult to clarify the
importance of a single gene in a disease process by genetic
studies alone.
As the presence of larger and more numerous drusen in the
macula is a common risk factor for AMD, the analysis of drusen
components has aided the understanding of AMD pathogenesis.
Components of the complement system are present in
significant quantity in drusen, further evidence that complement activation is important in the development of AMD.12,13
Drusen also contain many other proteins and lipoprotein-like
particles.14,15 Lipid profiles of such deposits have shown high
levels of lysophospholipids and free fatty acids, suggesting that
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hydrolysis of phospholipids, such as phosphatidylcholine, has
occurred.16,17 The Y402H polymorphism of complement
factor H (CFH) has been demonstrated to have a strong
association with AMD.2–5 The CFH is a regulator protein of
complement activation; it competes with factor B for binding
to C3b and functions as a cofactor for Factor I–mediated C3b
inactivation. The amino acid 402 of CFH is not involved with
C3b binding, but it has been demonstrated that the AMDassociated 402H variant of CFH has lower binding affinity to Creactive protein (CRP) than the 402Y variant.18,19 Patients with
AMD and individuals who are homozygous for the CFH 402H
haplotype have increased levels of CRP in drusen and basal
deposits,20,21 but the mechanisms of recruitment of CRP in
these patients remain unclear.
The AMD-associated SNP of hepatic lipase, rs10468017, is
located in the functional promoter region of the gene; its minor
T allele decreases hepatic lipase expression and has a
protective effect on the development of AMD.11 Hepatic
lipase, together with lipoprotein lipase and endothelial lipase,
comprise the triglyceride lipase gene subfamily, which has a
central role in plasma lipoprotein metabolism and homeostasis.
These lipases are differentiated by their tissue-specific gene
expression and substrate specificity. Lipoprotein lipase mainly
hydrolyzes triglycerides, whereas endothelial lipase exerts
significant phospholipase activity. Hepatic lipase (HL) appears
to have equal hydrolytic activities upon triglycerides and
phospholipids.22,23 The purpose of this study was to investigate the role of HL in modifying lipoproteins to become
bioactive in biological processes involved in AMD development, specifically complement activation via the CRP-mediated
classical pathway and direct RPE cell toxicity in vitro.

MATERIALS

AND

METHODS

Materials
Two different recombinant human HL preparations were used.
One was obtained from GeneTex (GTX48178-PRO; Irvine, CA,
USA) and the other purchased from OriGene (TP315870;
Rockville, MD, USA). Cholesterol esterase (CE) was obtained
from MP Biomedicals (0210543950; Solon, OH, USA). The 1,2bis(heptanoylthio)glycerophosphocholine, phosphocholine,
and horseradish peroxidase (HRP)-conjugated secondary antibody were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) was obtained from AbboMax (San Jose, CA, USA).
Lipoprotein-associated phospholipase A2 (Lp-PLA2) was purchased from R&D Systems (Minneapolis, MN, USA). Human
low-density lipoprotein (LDL), human high-density lipoprotein
(HDL), phospholipase C, human CRP, 1-Palmitoyl-sn-glycero-3phosphocholine (LPC [16:0]), 1-Oleoyl-sn-glycero-3-phosphocholine (LPC [18:1]), 2,3-dimercapto-1-propanol tributyrate
(DMPTB), and BSA prepared by heat shock fractionation were
obtained from Sigma-Aldrich (St. Louis, MO, USA). Human very
low-density lipoprotein (VLDL) was from Kalen Biomedical
(Montgomery Village, MD, USA). Normal human serum, C1qdepleted human serum, factor B-depleted human serum, and a
monoclonal antibody to a neoepitope in the C3d domain of C3
were obtained from Quidel (San Diego, CA, USA). All cell
culture products were from Life Technologies (Grand Island,
NY, USA).

Human LDL, VLDL, and HDL Degradation and
Complement Activation
The 96-well NUNC MaxiSorp plates were coated with 40 lL of
human LDL, VLDL, or HDL at 200 lg/mL in PBS at 48C
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overnight. The plates then were warmed to 378C for 1 hour
and remaining binding sites then were blocked with 3% BSA in
PBS at 378C for 1 hour. The wells were washed and then
incubated with 40 lL of HL, CE, or Lp-PLA2 in PBS containing
2% BSA at 378C for 1 or 2 hours as indicated in the Results
section. The degradation reaction was stopped by washing the
plate with PBS. For complement activation, the reacted plate
was incubated with 20 lL of 1:1 diluted human sera at 218C for
30 minutes. The diluent for serum dilutions was PBS
containing calcium and magnesium. Human sera that were
used in our study were native serum, C1q-depleted serum,
factor B-depleted serum, native serum with the addition of 10
mM MgCl2 and 2 mM EGTA (Mg-EGTA), and native serum with
the addition of 10 mM EDTA. After thorough washing of the
plate, complement component 3 (C3) fixation was determined
with anti-human C3d antibody in combination with HRPconjugated secondary antibody. The monoclonal anti-human
C3d antibody is reactive to all C3d-containing fragments of C3,
but not with C3 itself, so it can detect C3 fixation on the plate
and not simply C3 absorption. The final peroxidase activity
was monitored at 450 nm with 3,3 0 ,5,5 0 -tetramethyl-benzidine
and hydrogen peroxide as substrates after 10 to 15 minutes
reaction time at room temperature. Addition of EDTA to the
native human serum totally blocked complement activation;
thus it was used as a control for the complement activation
studies and was set as the baseline reading for every
experiment.

Enzymatic Activities
Triglyceride hydrolase activity of CE and HL was determined
using DMPTB as a substrate according to the method of Choi et
al.24 Phospholipase A activity of CE and HL was assayed
similarly as for its triglyceride hydrolase activity, but with 1.5
mM of 1,2-bis(heptanoylthio) glycerophosphocholine as a
substrate and by substituting 10 mM CaCl2 for 1 mM EDTA
in the assay buffer.25

Cell Culture and Cell Viability Assay
Human retinal pigment epithelial cell, ARPE-19, purchased
from ATCC (Manassas, VA, USA), were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% heatinactivated fetal bovine serum (FBS), 100 IU/mL of penicillin,
and 100 lg/mL of streptomycin (all cell culture products from
Invitrogen-Gibco, Rockville, MD, USA). Cells were maintained
at 378C in a 5% CO2 incubator with medium changes every 3 to
4 days. Subculture of cells was performed with a 0.05% trypsinEDTA solution.
Cell viability was determined using the colorimetric MTT
metabolic activity assay. ARPE-19 cells cultured in 96-well
cluster plates were incubated with 0.15 mL of serum-free
medium containing 0.5 mg/mL MTT at 378C for 2 hours in a 5%
CO2 incubator. After removal of the cell culture medium,
formation of formazan from MTT reduction was detected at
540 nm by adding 0.1 mL of dimethyl sulfoxide (DMSO).

Statistical Analysis
All values are presented as a mean 6 SD. Where applicable, a
2-tailed Student’s t-test was used to analyze the differences
between groups (Excel software; Microsoft, Redmond, WA,
USA). Minimum values of P less than 0.01 were considered
statistically significant and are denoted by an asterisk in each
figure.
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FIGURE 1. Phospholipase-digested human LDL, VLDL, and HDL can activate the classical pathway of the complement system. MaxiSorp plates (96well) were coated with fresh human LDL (A, D–F), VLDL (B), and HDL (C). After blocking with BSA, the plate was digested with HL (10 lg/mL for
[A–C, F], and 0–50 lg/mL for [D]) or Lp-PLA2 (0–50 lg/mL for [E]). The HL digestion time was 1 hour for (D), 2 hours for (A–C), and 0 to 2 hours
for (F). The Lp-PLA2 digestion time was 2 hours for (E). Color development was 15 minutes for (A–C, E, F) and 10 minutes for (D). To test
complement activation, the plate was incubated with dilute native human serum (N), C1q-depleted human serum (Cd), factor B-depleted human
serum (Bd), or human serum containing Mg-EGTA (ME). The C3 fixation on the plate then was detected with a monoclonal anti-C3d antibody
followed by HRP-conjugated secondary antibody. (A) Shows large statistically significant increases in complement activation for HL digested LDL.
Since increased C3 fixation was observed with normal and factor B-depleted serum, but not with either C1q-depleted or Mg-EGTA supplemented
serum, this indicates that activation is via the classical pathway (see text for further description). A similar response was observed using VLDL and
HDL, as shown in (B) and (C), respectively. (D, E) Show a concentration-dependent increase in C3 fixation induced by HL and Lp-PLA2 digestion of
LDL, respectively. The effect of HL digestion of LDL also was time-dependent (F).

RESULTS
HL Degradation of LDL, VLDL, and HDL Generates
Lipid Molecules That Can Activate the Classical
Complement Pathway
The HL degradation of human lipoproteins LDL, VLDL, or HDL
caused the modified lipoproteins to activate the complement
system (Fig. 1). The HL degradation of LDL, VLDL, and HDL
occurred through a calcium independent mechanism (data not
shown). The complement activation was dose- and timedependent upon HL degradation (Figs. 1D, 1F, respectively). To
identify which complement pathway was being activated, we
used known manipulations of the complement system from
native human serum. The C1q depletion prevents classical
pathway at initiation and the addition of Mg-EGTA chelates
calcium, a necessary component for classical pathway activation. Factor B depletion halts alternative pathway activation
from the beginning. When either C1q-depleted serum or MgEGTA–containing serum was used, complement activation did
not occur, indicating that the classical pathway is involved.
When factor B depleted serum was used, there was no change
in the level of complement activation, indicating that the
alternative pathway is not involved. We compared two
commercially available HL products (see Materials) with regard
to degradation of human lipoproteins, and both enzymes had
similar activities for modifying lipoproteins to activate the
complement system (data not shown). The HL from GeneTex
was used for most of our studies.

Lysophospholipids in Phospholipase-Digested
Lipoproteins Activate the Complement System
To identify the lipid molecules that can activate the classical
complement pathway in our system, we tested three lipases –
HL, CE, and Lp-PLA2 on generation of the lipid molecules. The
Lp-PLA2 can degrade phospholipids in lipoproteins into

lysophospholipids and fatty acids. As shown in Figure 1E, LpPLA2-digested LDL could activate complement system, implying that either lysophospholipids or fatty acids are the lipid
molecules that can activate the classical complement pathway
in our system. The CE has a broad spectrum of substrates that
include triglycerides, phospholipids, cholesterol esters. The
CE-digested LDL already is known to activate the complement
system via the classical pathway.26 Although HL and CE have
phospholipase A1 and triglyceride hydrolase activities, their
proportional enzymatic activities vary. Specifically, when
equivalent phospholipase A1 activity is present for CE and
HL, CE has significantly greater triglyceride hydrolase activity
than HL. As shown in Figure 2, we observed similar levels of
complement activation by using equivalent phospholipase A1
activity, 8 lUnits, of HL and CE, while their triglyceride
hydrolase activity displayed a >2700-times difference. This
suggests that phospholipase A1 activity is the primary
enzymatic activity that generates a complement-activating lipid
species in the setting of these enzymes. Triglyceride hydrolase
is known to digest LDL into fatty acids, monoglycerides, and
diglycerides, while phospholipase A1 is known to digest LDL
into fatty acids and lysophospholipids. Thus we can infer that
phospholipase activity is responsible for complement activation in this case and that the lysophospholipids likely mediate
this effect (i.e., are the complement activating lipid species in
these settings).

Inhibition of HL-Mediated Complement Activation
Phosphatidylcholine is the most abundant phospholipid in cell
membranes and lipoproteins, helping to maintain the structure
of the membrane. It then might be expected that the major
lysophospholipid generated from the phospholipase A1
activity of HL upon lipoproteins is lysophosphatidylcholine
(Fig. 3), a well-studied ligand for CRP in membrane structures.27 As it is known that immobilization of CRP can activate
the classical complement pathway by interaction with C1, we
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FIGURE 2. Phospholipase A1 activity of HL and CE is responsible for
the generation of complement-activating lipid molecules. Concentrations of HL and CE were normalized based on equivalent phospholipase A1 activity (8 lUnits each, data not shown). Immobilized LDL was
digested by each enzyme for 2 hours followed by the complement
activation assay using dilute native human serum (as in Fig. 1) and HRP
color development for 15 minutes. When normalized based on
phospholipase A1 activity, HL and CE have equivalent complement
activation activity, indicating that phospholipase A1 activity is
responsible for complement activation. In other words, if triglyceride
hydrolase activity were responsible for complement activation, a much
higher response from CE would have been expected since at this
concentration, the triglyceride hydrolase activity of each enzyme differ
markedly (3 lUnits for HL and 8125 lUnits for CE)

next focused upon ways of blocking the complement
activation due to lysophosphatidylcholine. When phosphocholine was added into native human serum as a competitive
binding inhibitor with lysophosphatidylcholine for CRP,28 it
dose-dependently decreased complement activation and approached a maximum inhibitory effect at 10 lM (Fig. 4A). In
addition, as shown in Figure 4B, phospholipase C, which
specifically cleaves phospholipids at the phosphate group, was
shown to reduce complement activation in a concentration
dependent manner. This latter finding further supports the
notion that the lipid species responsible for complement
activation are lysophospholipids.

CRP Enhances Complement Activation From HLDigested LDL
The CRP has multiple ligand binding sites and can bind
lysophosphatidylcholine, C1, and factor H to form a complex
structure. In further experiments, we studied the role of CRP
in lipoprotein-induced complement activation. As shown in
Figure 5, BSA alone, BSA with HL digestion, or native
undigested LDL did not activate the complement system. As
well, increasing the CRP level did not alter the complement

FIGURE 3. Hydrolysis of phosphatidylcholine occurs via the phospholipase A1 activity of the HL enzyme.
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FIGURE 4. Inhibition of HL-mediated complement activation. Plate
coating with human LDL and 2 hours of HL digestion were performed
as described in Figure 1. (A) Phosphocholine (0–50 lM), a competitive
binding inhibitor for CRP, was added into dilute native human serum
and the mixture was used for complement activation. (B) HL-digested
LDL was further reacted with phospholipase C (0–10 mU/mL), an
enzyme that specifically cleaves phosphocholine groups, followed by
complement activation. For both experiments, the HRP-catalyzed color
development was measured after a 15-minute incubation. As shown,
competitive inhibition of CRP binding by phosphocholine (A) as well
as elimination of the CRP binding ligand via phosphocholine cleavage
(B) are shown to reduce HL-mediated complement activation in a
concentration dependent manner.

activation activity of these molecules. In contrast, HL
degradation of LDL resulted in C3 fixation as well as a CRP
dose-dependent increase in complement activation. It should
be noted that an individual’s serum CRP level will vary in
different situations and can rise up dramatically in acute
inflammation, such as during an infection. Basal levels of CRP
also can be elevated in people with a variety of illnesses,
including AMD.29 Thus, elevated CRP levels may escalate
complement activation induced via a HL-mediated pathway.

Lysophosphatidylcholine is Cytotoxic to RPE Cells
We assessed the effects of lysophosphatidylcholine with regard
to cytotoxic activity against RPE cells. The saturated lysophospholipid 1-palmitoyl-sn-glycero-3-phosphocholine (LPC [16:0])
is one of the most predominant lysophospholipid products
resulting from the hydrolysis of biological membranes and is a
molecule with known cytotoxic activity toward many different
cell types, including endothelial cells, vascular smooth muscle
cells, and red blood cells.30–32 However, cytotoxicity to RPE
cells has not been reported previously to our knowledge. As
shown in Figure 6, LPC (16:0) displayed cytotoxicity to ARPE19 cells, a human RPE cell line, when it was added to the cell
culture medium at 20 lM or greater. Nearly all the cells were
killed when greater than 100 lM LPC (16:0) was used. ARPE-19

FIGURE 5. The CRP enhances complement activation from HL digested
LDL. Human LDL plate coating with a 1-hour HL digestion was
performed as described in Figure 1. Complement activation by HLdigested LDL was performed with dilute native human serum
supplemented with purified human CRP. The HRP-catalyzed color
development time was 10 minutes. The Figure shows that very little C3
fixation occurred in control samples that lacked either LDL coating or
HL digestion. In contrast, in samples containing both LDL and HL
digestion, the addition of CRP increased complement activation in a
concentration-dependent manner.

Bioactive Lysophospholipids Complement Activation

FIGURE 6. Cytotoxicity of lysophospholipids on ARPE-19 cells. The
ARPE-19 cells were cultured to 40% to 50% confluence in 96-well
plates, followed by a 24-hour incubation with serum-free medium. The
resultant cells were incubated with 0.1 mL of serum-free medium
containing 0 to 100 lM LPC (16:0) or LPC (18:1), or POPC for 22 hours.
Cell viability was determined using a standard MTT assay and cell
morphology was evaluated using light microscopy. The LPC (16:0) and
LPC (18:1) induced a concentration-dependent decrease in ARPE-19
viability, while POPC did not demonstrate cytotoxicity to ARPE-19 cells
at these concentrations.

cells displayed typical dead cell morphology after incubation
with 100 lM LPC (16:0) for 22 hours. As control, 1-palmitoyl-2oleoyl-sn-glycero-3-phosphocholine (POPC) did not show any
cytotoxicity on ARPE-19 cells when the same concentrations of
POPC was used in cell culture medium. The unsaturated
lysophospholipid, 1-Oleoyl-sn-glycero-3-phosphocholine (LPC
[18:1]), also was tested in its effect upon ARPE-19 cells, and it
displayed less toxicity though still substantial (Fig. 6).

DISCUSSION
In this study, we identified a molecular link between known
drusen components and several well-defined biological processes in the development of AMD, including complement
activation and RPE cell death. Our experimental data indicated
that the enzyme product of one AMD susceptibility gene,
hepatic lipase, can trigger the generation of bioactive
lysophospholipids, leading to complement activation via the
classical pathway. This complement activation can be escalated
by CRP binding. One of the best known genetic contributors
for AMD, CFH can bind with CRP and has a central role in
inhibiting complement activation at the C3b level. The 402H
variant of CFH has weaker binding to CRP, resulting in the loss
of its regulatory function and formation of membrane attack
complexes. We hypothesized that bioactive lysophospholipids,
in the setting of impaired CFH function, could lead to
unmitigated complement activation, with generation of inflammatory activity at the outer retinal layers. Thus, the RPE cells
that are in close proximity to drusen and basal deposits could
be one unintended target of this physiologic process. As we
have further demonstrated, lysophospholipid in sufficient
quantity can be cytotoxic to RPE cells and lead to RPE cell
death in vitro even in the absence of complement activation.
A common feature early in the pathogenesis of AMD is
deposit formation in the region of the RPE and Bruch’s
membrane interface. Accumulation of deposits in Bruch’s
membrane results in progressive Bruch’s membrane thickening
and the appearance of drusen. Lipoproteins are present in all
drusen, and many are in the form of lipoprotein-like particles
that contain apoA-I, apoB-100, apoE, apoC-I, and apoC-II.33,34
Furthermore, transmission electron micrographs of the lipoprotein-like particles accumulating underneath RPE cells in
AMD eyes show a morphology that is consistent with a model
of surface degradation and particle fusion.35 Such retained
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lipoprotein-like particles may be subject to oxidation and
degradation by local enzymes released from RPE cells (such as
HL, lipoprotein lipase, and secretory phospholipase A2), or
enzymes carried over via lipoproteins from the systemic
circulation (such as lipoprotein-associated phospholipase A2).
There are several lysophospholipid products of these enzymatic processes, such as lysophosphatidic acid, lysophosphatidylcholine, sphingosylphosphorylcholine, and sphingosine-1phosphate (S1P). Of note, anti-S1P therapy is being investigated as a new therapy for safety and efficacy in exudative AMD.36
A human RPE cell culture model that mimics early stages of
AMD displays an accumulation of sub-RPE deposits. Such
deposits consist of two morphologically distinct forms,
membrane-bound multivesicular material and nonmembranebound particle conglomerates.37 When exposed to human
serum, such deposits can trigger complement activation that
appears to be mediated via the classical pathway by binding of
C1q to ligands in the membrane-bound multivesicular material.
Such material contains apoE-rich deposits. In that cell culture
model system, IgG depletion had no detectable effect on
complement activation, suggesting that activation of the
classical pathway occurs via an antibody-independent mechanism. The exact C1q binding partners were not identified in
that study. Based upon our studies, it could be postulated that
phospholipases released from human RPE cells degrade apoEcontaining membrane deposits to generate lysophospholipids
capable of initiating complement activation via an antibodyindependent classical pathway.
A collaborative genome-wide association study, including
>17,100 advanced AMD cases and >60,000 controls of
European and Asian ancestry, identified 19 loci associated
with AMD at P < 5 3 108.38 To identify biological relationships
among these genetic association signals, the genes within 100
kb of the variants in each association peak were analyzed, and a
total of 90 genes was obtained when the correlation was set at
r2 > 0.8. Further analysis highlighted several biological
pathways, particularly the complement system, atherosclerotic
signaling, and angiogenesis, that were enriched in the resulting
set of 90 genes. Phospholipid degradation was also identified in
the top pathways with nominal P value at 0.0058. Three genes
were identified in the phospholipid pathway: PLA2G12A, LIPC
(hepatic lipase), and PLA2G6. The PLA2G12A is a secretory
phospholipase A2, while PLA2G6 is a cytosolic calciumindependent phospholipase A2. Compared to single-gene or
single-SNP analyses, such gene set/pathway association analyses can potentially reduce false positives and uncover a
significant biological effect distributed over multiple loci even
if changes in any individual locus have a small effect. As an
example relevant to our study, each of the three genes in the
phospholipid degradation pathway has a weak association with
AMD, but together they form a pathway that has a strong
association with AMD.
Lysophospholipids, at 10 to 100 lM, have well-known
cytotoxicity to many different cell types and are studied
extensively in the pathogenesis of atherosclerosis.39,40 Our
study demonstrated lysophospholipids also are cytotoxic to
RPE cells when similar levels of lysophosphatidylcholine were
present in medium. While we did not investigate multiple
chemical moieties, our findings suggested that saturated
lysophospholipids may be more cytotoxic than unsaturated
species to ARPE-19 cells. The specific bioactive lysophospholipids that may be relevant to the pathogenesis of retinal
disease, like AMD, are not yet known. The viability studies
were performed with one cell line in our study, and other
retinal cells may have different responses to different
molecular species of lysophospholipids.
We end by summarizing a proposed damage mechanism
based upon the findings of this study. Subretinal lipoproteins,
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such as HDL, VLDL, LDL, and lipoprotein-like particles, have an
important role in the normal lipid transport mechanisms of the
outer retina. These lipoproteins accumulate in the outer retina
with age where they may serve as substrates for enzymatic
modifications. The HL, and likely other enzymes in the outer
retina with phospholipase activity, can digest these lipoproteins to form products that can initiate activation of the
classical pathway of the complement system. Based upon
genetic studies, there is likely to be phenotypic variation in
phospholipase activity and, thus, the modification of phospholipids. Some eyes, such as those in individuals with a CFH
deficiency and other polymorphisms, have a lessened ability to
regulate or inhibit local complement activation, making them
particularly susceptible to the deleterious effects of bioactive
lipids. In such cases, bioactive lipids may serve as triggers for
sustained complement activation and/or RPE cellular dysfunction, ultimately contributing to the development of AMD in its
various forms.
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